Cosmetic composition containing c-glycoside, nicotinamide and panthenol

Abstract

A cosmetic composition comprising, in a physiologically acceptable medium and for the total weight of the composition, by weight of active material: from 1% to 25% of at least one C-glycoside of formula (I); from 1% to 10% of a compound chosen from nicotinamide and derivatives thereof; and from 0.5% to 10% of panthenol. The invention also relates to a non-therapeutic cosmetic care process for keratin materials, in particular the skin, comprising: applying to said keratin materials, in particular the skin, the composition of the invention.

Description

Technical Field

[0001] This invention relates to a cosmetic composition comprising, in a given amount, a physiologically acceptable medium, at least one C-glycoside of formula (I); nicotinamide or a derivative thereof; and panthenol. Background Technology

[0002] Skin is a tissue in which cells are tightly connected and firmly attached to each other. Skin tissue is the outermost layer of the body containing sebaceous or sweat glands and hair follicles. Skin (especially the scalp) is a constantly renewing epithelial tissue. This renewal, also known as desquamation, is a coordinated and precisely regulated process that results in the removal of surface cells in a way that is imperceptible and invisible to the naked eye.

[0003] Human skin consists of two parts: the superficial layer (epidermis) and the deep layer (dermis).

[0004] Traditionally, the epidermis is further divided into: the basal layer, composed of keratinocytes, which is also the germinal layer of the epidermis; the so-called "spinous layer," composed of several layers of polyhedral cells located on the germinal layer; one to three granular layers, composed of flattened cells containing the unique cytoplasmic contents of keratinocytes; and a series of so-called stratum corneum, which is composed of keratinocytes in the terminal stage of differentiation.

[0005] A major trend among consumers today is the desire to maintain a youthful appearance for as long as possible. To this end, consumers are committed to diminishing signs of skin aging (such as wrinkles and fine lines, thinning of the epidermis, weakened skin barrier function, and / or the appearance of sagging and wrinkles) and / or delaying the signs of aging. For this reason, numerous products have been developed to maintain youthful radiance and wrinkle-free skin for as long as possible. These products contain one or more bioactive ingredients with proven efficacy against skin aging.

[0006] However, the performance of such products still needs further improvement.

[0007] Therefore, there is currently a demand for products that offer one or more benefits in anti-aging. Specifically, there is a demand for products that can achieve the following effects: more even skin texture; and / or smaller / tighter pores; and / or a tired-looking effect; and / or a reduction in wrinkles and / or fine lines; and / or a more elastic appearance; and / or a softer, more supple complexion. Summary of the Invention

[0008] The inventors have now discovered that when formula (I) C-glycoside is combined with nicotinamide and panthenol in a given amount, one or more benefits in anti-aging can be satisfactorily achieved and the above-mentioned problems can be solved.

[0009] Accordingly, the present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, the following components in the total weight of the composition as follows:

[0010] At least one (I)C-glycoside, comprising 1% to 25% by weight of the active substance;

[0011] Compounds selected from nicotinamide and its derivatives, comprising 1% to 10% by weight of the active substance; and

[0012] Panthenol, comprising 0.5% to 10% by weight of the active substance.

[0013] The present invention also relates to a non-therapeutic cosmetic care method for keratin substances, especially skin, comprising: applying the composition of the present invention to keratin substances, especially skin.

[0014] This invention also relates to the cosmetic use of the compositions of this invention in reducing signs of skin aging. Detailed Implementation

[0015] The compound of formula (I) C-glycoside with nicotinamide and panthenol in a given amount is also called "the compound of the present invention".

[0016] The following examples demonstrate that this combination has a stronger or better effect, especially enhancing the effect of C-glycosides. In fact, nicotinamide or a derivative thereof combined with panthenol enhances the effect of C-glycosides, significantly increasing their efficacy.

[0017] In this invention, "enhanced effect" means that the reaction or effect produced when various components are combined and put into practical use is greater than the sum of the reactions or effects produced when these components are put into practical use individually.

[0018] In this invention, "physiologically acceptable medium" refers to a medium that is compatible with keratinous substances such as skin, mucous membranes, nails and / or hair.

[0019] C-glycosides

[0020] The C-glycosides of the present invention have the following general formula (I):

[0021] (I)

[0022] in:

[0023] - R indicates:

[0024] - C1~C20, especially C1~C10 saturated straight-chain alkyl, or C2~C20, especially C3~C10 unsaturated straight-chain alkyl, or C3~C20, especially C4~C10 saturated or unsaturated branched or cycloalkyl;

[0025] - C1~C20, especially C2~C10 saturated straight-chain hydrofluoric or perfluoroalkyl, or C2~C20, especially C2~C10 unsaturated straight-chain hydrofluoric or perfluoroalkyl, or C3~C20, especially C4~C10 saturated or unsaturated branched or cyclic hydrofluoric or perfluoroalkyl;

[0026] - Phenyl or benzyl, wherein the hydrocarbon chain constituting the group may optionally be interrupted by one, two, three or more heteroatoms selected from the following heteroatoms, where applicable:

[0027] - Oxygen atom;

[0028] - Sulfur atom;

[0029] - Nitrogen atom; and

[0030] - Silicon atoms,

[0031] Furthermore, it may be substituted with at least one of the following groups:

[0032] - OR4;

[0033] - -SR4;

[0034] - -NR4R5;

[0035] - -COOR4;

[0036] - -CONHR4;

[0037] - -CN;

[0038] - Halogen atom;

[0039] - C1~C6 hydrofluoric or perfluoroalkyl, and / or

[0040] - C3~C8 cycloalkyl groups, and / or

[0041] - At least one optional substitute for C5~C 18 cycloalkyl, aryl or heterocyclic groups,

[0042] Among them, R4 and R5 can each represent a hydrogen atom individually, or C1~C1. 30 Especially C3~C 12 Saturated straight-chain alkyl, perfluoroalkyl, or hydrofluoroalkyl, or C2~C 30 Especially C3~C 12Unsaturated straight-chain alkyl, perfluoroalkyl, or hydrofluoroalkyl, or saturated or unsaturated C3~C 30 Especially C4~C 12 Branched or cyclic alkyl groups, perfluoroalkyl groups, or hydrofluoroalkyl groups, or C6~C 10 Aryl;

[0043] - X represents a group selected from -CO-, -CH(OH)-, and -CH(NH2)-, with -CH(OH)- being preferred;

[0044] - S represents a monosaccharide in the form of pyranose and / or furanose and in the configuration of L and / or D, or a polysaccharide containing up to 20 sugar units, particularly up to 6 sugar units, wherein the monosaccharide or polysaccharide may be substituted with hydroxyl groups that must remain free, and may be substituted with one or more optional protected amine functional groups;

[0045] - The S-CH2-X bond represents an anomeric carbon bond, which can be either an α-anomeric bond or a β-anomeric bond.

[0046] And its physiologically acceptable solvates such as salts and hydrates, as well as isomers.

[0047] Within the scope of this invention, "halogen" refers to chlorine, fluorine, bromine, or iodine.

[0048] The term “aryl” refers to an aromatic ring system that may be substituted with one or more C1-C4 alkyl groups, such as phenyl.

[0049] The term "C3~C8 cycloalkyl" refers to aliphatic ring systems with 3 to 8 carbon atoms, such as cyclopropyl, cyclopentyl, and cyclohexyl.

[0050] The alkyl groups suitable for implementation of the present invention may be, in particular, methyl, ethyl, isopropyl, n-propyl, n-butyl, tert-butyl, isobutyl, sec-butyl, pentyl, n-hexyl, cyclopropyl, cyclopentyl, cyclohexyl and allyl.

[0051] In C-glycosides conforming to formula (I): S may represent a monosaccharide in the form of pyranose and / or furanose and configured as L and / or D, or a polysaccharide containing up to 6 sugar units, the monosaccharide or polysaccharide having at least one hydroxyl functional group that must remain free, and / or optionally having one or more amine functional groups that must be protected; X and R are defined exactly as above.

[0052] As an advantageous embodiment, the monosaccharide of the present invention may be selected from D-glucose, D-galactose, D-mannose, D-xylose, D-lythose, L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine, and N-acetyl-D-galactosamine. As an advantageous embodiment, the monosaccharide is D-glucose, D-xylose, N-acetyl-D-glucosamine, or L-fucose, particularly D-xylose.

[0053] More specifically, the polysaccharide of the present invention containing up to six sugar units may be selected from: D-maltose; D-lactose; D-cellobiose; D-maltotriose; disaccharides obtained by combining uronic acid selected from D-iduronic acid and D-glucuronic acid with hexosamine selected from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine and N-acetyl-D-glucosamine; and oligosaccharides containing at least one xylose. As an advantageous embodiment, the oligosaccharide may be selected from xylobiose, methyl-β-xylobiose, xylotriose, xylotetraose, xylopentose, and xylohexaose, preferably xylobiose composed of two xylose molecules linked by a 1,4-bond.

[0054] More specifically, S may represent a monosaccharide selected from D-glucose, D-xylose, L-fucose, D-galactose and D-maltose, especially D-xylose.

[0055] According to one embodiment of the present invention, a C-glycoside conforming to formula (I) can be used, wherein R represents a C1-C glycoside that is optionally substituted as described above. 20 Especially C1~C 10 Saturated straight-chain alkyl groups, or C2~C 20 Especially C3~C 10 Unsaturated straight-chain alkyl, or C3~C 20 Especially C4~C 10 Saturated or unsaturated branched or cycloalkyl groups, the definitions of S and X are exactly the same as above.

[0056] R may particularly represent a C1-C4, especially C1-C2 straight-chain group optionally substituted with -OH, -COOH or -COOR''2, wherein R''2 is a C1-C4 saturated straight-chain alkyl group, especially methyl. R may particularly represent an unsubstituted C1-C4, especially C1-C2 straight-chain alkyl group, especially methyl.

[0057] Among various (I) C-glycosides, the following C-glycosides may be used in particular:

[0058] - R represents the C1~C that can be optionally substituted in the manner described above. 20 Especially C1~C 10 Saturated straight-chain alkyl groups, or C2~C 20 Especially C3~C10 Unsaturated straight-chain alkyl, or C3~C 20 Especially C4~C 10 Saturated or unsaturated branched or cycloalkyl groups;

[0059] - S represents the monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, especially D-xylose;

[0060] - X represents a group selected from -CO-, -CH(OH)- and -CH(NH2)-, with -CH(OH)- being preferred.

[0061] More specifically, use the following formula (I) C-glycoside:

[0062] - R represents a C1-C4, especially C1-C3 straight-chain group that is optionally substituted by -OH, -COOH or -COOR''2, wherein R''2 is a C1-C4 saturated straight-chain alkyl group, especially methyl;

[0063] - S represents the monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, especially D-xylose;

[0064] - X represents a group selected from -CO-, -CH(OH)-, and -CH(NH2)-, with -CH(OH)- being preferred.

[0065] According to one embodiment, C-glycosides of the following formula (I) can be used:

[0066] - R represents an unsubstituted C1~C4, especially C1~C2 straight-chain alkyl, especially methyl;

[0067] - S represents the monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, especially D-xylose;

[0068] - X represents a group selected from -CO-, -CH(OH)-, and -CH(NH2)-, with -CH(OH)- being preferred.

[0069] For non-therapeutic uses of the compounds described in this invention, the aforementioned acceptable salts include common non-toxic salts of the compounds, such as non-toxic salts formed from organic or inorganic acids. Such salts are, for example, salts of mineral acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, and boric acid. Such salts can also be salts of organic acids that may contain one or more carboxylic acid groups, sulfonic acid groups, or phosphonic acid groups. Such organic acids may include straight-chain, branched, or cyclic aliphatic acids, or aromatic acids. Such acids may further contain one or more heteroatoms selected from O and N, in the form of, for example, a hydroxyl group. Such acids may be particularly propionic acid, acetic acid, terephthalic acid, citric acid, and tartaric acid.

[0070] When the compound of formula (I) contains an acid group, the acid group can be neutralized by a mineral base such as LiOH, NaOH, KOH, Ca(OH)2, NH4OH, Mg(OH)2, or Zn(OH)2, or by an organic base such as an alkyl primary amine, alkyl secondary amine, or alkyl tertiary amine (e.g., triethylamine or butylamine). The alkyl primary amine, alkyl secondary amine, or alkyl tertiary amine may contain one or more nitrogen atoms and / or oxygen atoms, and thus may contain, for example, one or more alcohol functional groups. Such amines may be, in particular, amino-2-methyl-2-propanol, triethanolamine, dimethylamino-2-propanol, 2-amino-2-hydroxymethyl-1,3-propanediol, and may also be lysine or 3-dimethylaminopropylamine.

[0071] For the compounds described in this invention, acceptable solvates include common solvates formed in the final preparation steps of the compound due to the presence of a solvent, such as solvates formed due to the presence of straight-chain alcohols or branched-chain alcohols such as water, ethanol, or isopropanol.

[0072] Among the various formula (I) C-glycosides used in this invention, the following are particularly preferred:

[0073] 1. C-β-D-xylanopyranoside-n-propyl-2-one;

[0074] 2. C-α-D-xylanopyranoside-n-propyl-2-one;

[0075] 3. 1-[2-(3-hydroxypropylamino)-propyl]-C-β-D-xylanose;

[0076] 4. 1-[2-(3-hydroxypropylamino)-propyl]-C-α-D-xylanose;

[0077] 5. C-β-D-xylanopyranoside-2-hydroxypropane;

[0078] 6. C-α-D-xylanopyranoside-2-hydroxypropane;

[0079] 7. C-β-D-xylanopyranoside-2-aminopropane;

[0080] 8. C-α-D-xylanopyranoside-2-aminopropane;

[0081] 9. C-β-D-xylanopyranoside-2-phenylaminopropane;

[0082] 10. C-α-D-xylanopyranoside-2-phenylaminopropane;

[0083] 11. Ethyl 3-methyl-4-(C-β-D-xylanopyranoside)-butyrate;

[0084] 12. Ethyl 3-methyl-4-(C-α-D-xylanopyranoside)-butyrate;

[0085] 13. 6-(C-β-D-xylanopyranoside)-5-oxohexanoic acid;

[0086] 14. 6-(C-α-D-xylanopyranoside)-5-oxohexanoic acid;

[0087] 15. 6-(C-β-D-xylanopyranoside)-5-hydroxyhexanoic acid;

[0088] 16. 6-(C-α-D-xylanopyranoside)-5-hydroxyhexanoic acid;

[0089] 17. 6-(C-β-D-xylanopyranoside)-5-aminohexanoic acid;

[0090] 18. 6-(C-α-D-xylanopyranoside)-5-aminohexanoic acid;

[0091] 19. 6-(C-β-D-xylanopyranoside)-5-phenylaminohexanoic acid;

[0092] 20. 6-(C-α-D-xylanopyranoside)-5-phenylaminohexanoic acid;

[0093] 21. 1-(C-β-D-xylanopyranoside)-2,6-hexanediol;

[0094] 22. 1-(C-α-D-xylanopyranoside)-2,6-hexanediol;

[0095] 23. 5-(C-β-D-xylanopyranoside)-4-oxovaleric acid;

[0096] 24. 5-(C-α-D-xylanopyranoside)-4-oxovaleric acid;

[0097] 25. 5-(C-β-D-xylanopyranoside)-4-hydroxyvalerate;

[0098] 26. 5-(C-α-D-xylanopyranoside)-4-hydroxyvalerate;

[0099] 27. 5-(C-β-D-xylanopyranoside)-4-aminovaleric acid;

[0100] 28. 5-(C-α-D-xylanopyranoside)-4-aminovaleric acid;

[0101] 29. 5-(C-β-D-xylanopyranoside)-4-phenylaminovaleric acid;

[0102] 30. 5-(C-α-D-xylanopyranoside)-4-phenylaminovaleric acid;

[0103] 31. 1-(C-β-D-xylanopyranoside)-2,5-pentanediol;

[0104] 32. 1-(C-α-D-xylanopyranoside)-2,5-pentanediol;

[0105] 33. 1-(C-β-D-pyranofucoloside)-propan-2-one;

[0106] 34. 1-(C-α-D-pyranofucoloside)-propan-2-one;

[0107] 35. 1-(C-β-L-pyranofucoloside)-propan-2-one;

[0108] 36. 1-(C-α-L-pyranofucoloside)-propan-2-one;

[0109] 37. 1-(C-β-D-pyranofucoloside)-2-hydroxypropane;

[0110] 38. 1-(C-α-D-pyranofucoloside)-2-hydroxypropane;

[0111] 39. 1-(C-β-L-pyranofucoloside)-2-hydroxypropane;

[0112] 40. 1-(C-α-L-pyranofucoloside)-2-hydroxypropane;

[0113] 41. 1-(C-β-D-pyranofucoloside)-2-aminopropane;

[0114] 42. 1-(C-α-D-pyranofucoloside)-2-aminopropane;

[0115] 43. 1-(C-β-L-pyranofucoloside)-2-aminopropane;

[0116] 44. 1-(C-α-L-pyranofucoloside)-2-aminopropane;

[0117] 45. 1-(C-β-D-pyranofucoloside)-2-phenylaminopropane;

[0118] 46. ​​1-(C-α-D-pyranofucoloside)-2-phenylaminopropane;

[0119] 47. 1-(C-β-L-pyranofucoloside)-2-phenylaminopropane;

[0120] 48. 1-(C-α-L-pyranofucoloside)-2-phenylaminopropane;

[0121] 49. Ethyl 3-methyl-4-(C-β-D-pyranofucoloside)-butyrate;

[0122] 50. Ethyl 3-methyl-4-(C-α-D-pyranofucoloside)-butyrate;

[0123] 51. Ethyl 3-methyl-4-(C-β-L-pyranofucoloside)-butyrate;

[0124] 52. Ethyl 3-methyl-4-(C-α-L-pyranofucoloside)-butyrate;

[0125] 53. 6-(C-β-D-pyranofucoloside)-5-oxohexanoic acid;

[0126] 54. 6-(C-α-D-pyranofucoloside)-5-oxohexanoic acid;

[0127] 55. 6-(C-β-L-pyranofucoloside)-5-oxohexanoic acid;

[0128] 56. 6-(C-α-L-pyranofucoloside)-5-oxohexanoic acid;

[0129] 57. 6-(C-β-D-pyranofucoloside)-5-hydroxyhexanoic acid;

[0130] 58. 6-(C-α-D-pyranofucoloside)-5-hydroxyhexanoic acid;

[0131] 59. 6-(C-β-L-pyranofucoloside)-5-hydroxyhexanoic acid;

[0132] 60. 6-(C-α-L-pyranofucoloside)-5-hydroxyhexanoic acid;

[0133] 61. 6-(C-β-D-pyranofucoloside)-5-aminohexanoic acid;

[0134] 62. 6-(C-α-D-pyranofucoloside)-5-aminohexanoic acid;

[0135] 63. 6-(C-β-L-pyranofucoloside)-5-aminohexanoic acid;

[0136] 64. 6-(C-α-L-pyranofucoloside)-5-aminohexanoic acid;

[0137] 65. 1-(C-β-D-pyranofucoloside)-2,6-hexanediol;

[0138] 66. 1-(C-α-D-pyranofucoloside)-2,6-hexanediol;

[0139] 67. 1-(C-β-L-pyranofucoloside)-2,6-hexanediol;

[0140] 68. 1-(C-α-L-pyranofucoloside)-2,6-hexanediol;

[0141] 69. 5-(C-β-D-pyranofucoloside)-4-oxovaleric acid;

[0142] 70. 5-(C-α-D-pyranofucoloside)-4-oxovaleric acid;

[0143] 71. 5-(C-β-L-pyranofucoloside)-2,6-hexanediol)-4-oxovaleric acid;

[0144] 72. 5-(C-α-L-pyranofucoloside)-2,6-hexanediol)-4-oxovaleric acid;

[0145] 73. 5-(C-β-D-pyranofucoloside)-4-hydroxyvalerate;

[0146] 74. 5-(C-α-D-pyranofucoloside)-4-hydroxyvalerate;

[0147] 75. 5-(C-β-L-pyranofucoloside)-4-hydroxyvalerate;

[0148] 76. 5-(C-α-L-pyranofucoloside)-4-hydroxyvalerate;

[0149] 77. 5-(C-β-D-pyranofucoloside)-4-aminovaleric acid;

[0150] 78. 5-(C-α-D-pyranofucoloside)-4-aminovaleric acid;

[0151] 79. 5-(C-β-L-pyranofucoloside)-4-aminovaleric acid;

[0152] 80. 5-(C-α-L-pyranofucoloside)-4-aminovaleric acid;

[0153] 81. 1-(C-β-D-pyranofucoloside)-2,5-pentanediol;

[0154] 82. 1-(C-α-D-pyranofucoloside)-2,5-pentanediol;

[0155] 83. 1-(C-β-L-pyranofucoloside)-2,5-pentanediol;

[0156] 84. 1-(C-α-L-pyranofucoloside)-2,5-pentanediol;

[0157] 85. 1-(C-β-D-glucopyranosyl)-2-hydroxypropane;

[0158] 86. 1-(C-α-D-glucopyranosyl)-2-hydroxypropane;

[0159] 87. 1-(C-β-D-glucopyranosyl)-2-aminopropane;

[0160] 88. 1-(C-α-D-glucopyranosyl)-2-aminopropane;

[0161] 89. 1-(C-β-D-glucopyranosyl)-2-phenylaminopropane;

[0162] 90. 1-(C-α-D-glucopyranosyl)-2-phenylaminopropane;

[0163] 91. Ethyl 3-methyl-4-(C-β-D-glucopyranosyl)-butyrate;

[0164] 92. Ethyl 3-methyl-4-(C-α-D-glucopyranosyl)-butyrate;

[0165] 93. 6-(C-β-D-glucopyranosyl)-5-oxohexanoic acid;

[0166] 94. 6-(C-α-D-glucopyranosyl)-5-oxohexanoic acid;

[0167] 95. 6-(C-β-D-glucopyranosyl)-5-hydroxyhexanoic acid;

[0168] 96. 6-(C-α-D-glucopyranosyl)-5-hydroxyhexanoic acid;

[0169] 97. 6-(C-β-D-glucopyranosyl)-5-aminohexanoic acid;

[0170] 98. 6-(C-α-D-glucopyranosyl)-5-aminohexanoic acid;

[0171] 99. 6-(C-β-D-glucopyranosyl)-5-phenylaminohexanoic acid;

[0172] 100, 6-(C-α-D-glucopyranosyl)-5-phenylaminohexanoic acid;

[0173] 101. 1-(C-β-D-glucopyranosyl)-2,6-hexanediol;

[0174] 102. 1-(C-α-D-glucopyranosyl)-2,6-hexanediol;

[0175] 103, 6-(C-β-D-glucopyranosyl)-5-oxovaleric acid;

[0176] 104, 6-(C-α-D-glucopyranosyl)-5-oxovaleric acid;

[0177] 105, 6-(C-β-D-glucopyranosyl)-5-hydroxyvalerate;

[0178] 106. 6-(C-α-D-glucopyranosyl)-5-hydroxyvalerate;

[0179] 107. 6-(C-β-D-glucopyranosyl)-5-aminovaleric acid;

[0180] 108. 6-(C-α-D-glucopyranosyl)-5-hydroxyvalerate;

[0181] 109. 6-(C-β-D-glucopyranosyl)-5-phenylaminovaleric acid;

[0182] 110, 6-(C-α-D-glucopyranosyl)-5-phenylaminovaleric acid;

[0183] 111, 1-(C-β-D-glucopyranosyl)-2,5-pentanediol;

[0184] 112, 1-(C-α-D-glucopyranosyl)-2,5-pentanediol;

[0185] 113. 1-(C-β-D-galactopyranosyl)-2-hydroxypropane;

[0186] 114. 1-(C-α-D-galactopyranosyl)-2-hydroxypropane;

[0187] 115. 1-(C-β-D-galactopyranosyl)-2-aminopropane;

[0188] 116. 1-(C-α-D-galactopyranosyl)-2-aminopropane;

[0189] 117. 1-(C-β-D-galactopyranosyl)-2-phenylaminopropane;

[0190] 118. 1-(C-α-D-galactopyranosyl)-2-phenylaminopropane;

[0191] 119. Ethyl 3-methyl-4-(β-D-galactopyranosyl)-butyrate;

[0192] 120. Ethyl 3-methyl-4-(α-D-galactopyranosyl)-butyrate;

[0193] 121, 6-(C-β-D-galactopyranosyl)-5-oxohexanoic acid;

[0194] 122, 6-(C-α-D-galactopyranosyl)-5-oxohexanoic acid;

[0195] 123, 6-(C-β-D-galactopyranosyl)-5-hydroxyhexanoic acid;

[0196] 124, 6-(C-α-D-galactopyranosyl)-5-hydroxyhexanoic acid;

[0197] 125, 6-(C-β-D-galactopyranosyl)-5-aminohexanoic acid;

[0198] 126. 6-(C-α-D-galactopyranosyl)-5-aminohexanoic acid;

[0199] 127. 6-(C-β-D-galactopyranosyl)5-phenylaminohexanoic acid;

[0200] 128, 6-(C-α-D-galactopyranosyl)5-phenylaminohexanoic acid;

[0201] 129. 1-(C-β-D-galactopyranosyl)-2,6-hexanediol;

[0202] 130, 1-(C-α-D-galactopyranosyl)-2,6-hexanediol;

[0203] 131, 6-(C-β-D-galactopyranosyl)-5-oxovaleric acid;

[0204] 132, 6-(C-α-D-galactopyranosyl)-5-oxovaleric acid;

[0205] 133, 6-(C-β-D-galactopyranosyl)-5-hydroxyvalerate;

[0206] 134, 6-(C-α-D-galactopyranosyl)-5-hydroxyvalerate;

[0207] 135, 6-(C-β-D-galactopyranosyl)-5-aminovaleric acid;

[0208] 136, 6-(C-α-D-galactopyranosyl)-5-aminovaleric acid;

[0209] 137. 6-(C-β-D-galactopyranosyl)-5-phenylaminovaleric acid;

[0210] 138. 6-(C-α-D-galactopyranosyl)-5-phenylaminovaleric acid;

[0211] 139. 1-(C-β-D-galactopyranosyl)-2,6-pentanediol;

[0212] 140. 1-(C-α-D-galactopyranosyl)-2,6-pentanediol;

[0213] 141, 1-(C-β-D-furanfucosyl)-propan-2-one;

[0214] 142, 1-(C-α-D-furanfucosyl)-propan-2-one;

[0215] 143, 1-(C-β-L-furanfucosyl)-propan-2-one;

[0216] 144, 1-(C-α-L-furanfucosyl)-propan-2-one;

[0217] 145, 3'-(acetamido-C-β-D-glucopyranosyl)-propion-2'-one;

[0218] 146. 3'-(acetamido-C-α-D-glucopyranosyl)-propion-2'-one;

[0219] 147. 1-(acetamido-C-β-D-glucopyranosyl)-2-hydroxypropane;

[0220] 148. 1-(acetamido-C-β-D-glucopyranosyl)-2-aminopropane;

[0221] 149. 1-(acetamido-C-β-D-glucopyranosyl)-2-phenylaminopropane;

[0222] 150, 1-(acetamido-C-α-D-glucopyranosyl)-2-phenylaminopropane;

[0223] 151. Ethyl 3-methyl-4-(acetamido-C-β-D-glucopyranoyl)-butyrate

[0224] 152. Ethyl 3-methyl-4-(acetamido-C-α-D-glucopyranosyl)-butyrate

[0225] 153, 6-(acetamido-C-β-D-glucopyranosyl)-5-oxohexanoic acid;

[0226] 154, 6-(acetamido-C-α-D-glucopyranosyl)-5-oxohexanoic acid;

[0227] 155, 6-(acetamido-C-β-D-glucopyranosyl)-5-hydroxyhexanoic acid;

[0228] 156, 6-(acetamido-C-α-D-glucopyranosyl)-5-hydroxyhexanoic acid;

[0229] 157. 6-(acetamido-C-β-D-glucopyranosyl)-5-aminohexanoic acid;

[0230] 158, 6-(acetamido-C-α-D-glucopyranosyl)-5-aminohexanoic acid;

[0231] 159. 6-(acetamido-C-β-D-glucopyranosyl)-5-phenylaminohexanoic acid;

[0232] 160, 6-(acetamido-C-α-D-glucopyranosyl)-5-phenylaminohexanoic acid;

[0233] 161. 1-(acetamido-C-β-D-glucopyranosyl)-2,6-hexanediol;

[0234] 162, 1-(acetamido-C-α-D-glucopyranosyl)-2,6-hexanediol;

[0235] 163, 6-(acetamido-C-β-D-glucopyranosyl)-5-oxovaleric acid;

[0236] 164, 6-(acetamido-C-α-D-glucopyranosyl)-5-oxovaleric acid;

[0237] 165, 6-(acetamido-C-β-D-glucopyranosyl)-5-hydroxyvalerate;

[0238] 166, 6-(acetamido-C-α-D-glucopyranosyl)-5-hydroxyvalerate;

[0239] 167. 6-(acetamido-C-β-D-glucopyranosyl)-5-aminovaleric acid;

[0240] 168. 6-(acetamido-C-α-D-glucopyranosyl)-5-aminovaleric acid;

[0241] 169. 6-(acetamido-C-β-D-glucopyranosyl)-5-phenylaminovaleric acid;

[0242] 170, 6-(acetamido-C-α-D-glucopyranosyl)-5-phenylaminovaleric acid;

[0243] 171. 1-(acetamido-C-β-D-glucopyranosyl)-2,5-pentanediol;

[0244] 172, 1-(acetamido-C-α-D-glucopyranosyl)-2,5-pentanediol.

[0245] For illustrative and not limiting purposes, the C-glycosides suitable for use in this invention may more specifically include, in particular, the following compounds:

[0246] - C-β-D-xylanopyranoside-n-propion-2-one;

[0247] - C-α-D-xylanopyranoside-n-propion-2-one;

[0248] - C-β-D-xylanopyranoside-2-hydroxypropane;

[0249] - C-α-D-xylanopyranoside-2-hydroxypropane;

[0250] - 1-(C-β-D-pyranofucoloside)-propan-2-one;

[0251] - 1-(C-α-D-pyranofucoloside)-propan-2-one;

[0252] - 1-(C-β-L-pyranofucoloside)-propan-2-one;

[0253] - 1-(C-α-L-pyranofucoloside)-propion-2-one;

[0254] - 1-(C-β-D-pyranofucoloside)-2-hydroxypropane;

[0255] - 1-(C-α-D-pyranofucoloside)-2-hydroxypropane;

[0256] - 1-(C-β-L-pyranofucoloside)-2-hydroxypropane;

[0257] - 1-(C-α-L-pyranofucoloside)-2-hydroxypropane;

[0258] - 1-(C-β-D-glucopyranosyl)-2-hydroxypropane;

[0259] - 1-(C-α-D-glucopyranosyl)-2-hydroxypropane;

[0260] - 1-(C-β-D-galactopyranosyl)-2-hydroxypropane;

[0261] - 1-(C-α-D-galactopyranosyl)-2-hydroxypropane;

[0262] - 1-(C-β-D-furanfucosyl)-propan-2-one;

[0263] - 1-(C-α-D-furanfucosyl)-prop-2-one;

[0264] - 1-(C-β-L-furanfucosyl)-prop-2-one;

[0265] - 1-(C-α-L-furanfucosyl)-prop-2-one;

[0266] - C-β-D-malpyranoside-n-propan-2-one;

[0267] - C-α-D-pyranomaltoside-n-propan-2-one;

[0268] - C-β-D-malopyranoside-2-hydroxypropane;

[0269] - C-α-D-pyranomaltoside-2-hydroxypropane; its isomers; or mixtures thereof.

[0270] Preferably, C-β-D-xylanopyranoside-2-hydroxypropane or C-α-D-xylanopyranoside-2-hydroxypropane is used, more preferably C-β-D-xylanopyranoside-2-hydroxypropane. Preferably, as an advantageous embodiment, the C-glycoside of formula (I) suitable for the present invention can be C-β-D-xylanopyranoside-2-hydroxypropane, the INCI name of which is "hydroxypropyl tetrahydropyranoside", particularly sold by Novéal under the names MEXORYL SBB® or MEXORYL SCN®. Such C-glycosides of formula (I) can also exist in a concentrated form, i.e., as an active substance concentrated to 70% in a hydrophilic dispersant. Such C-glycosides are commercially available by Novéal under the name MEXORYL SCS®.

[0271] The composition of the present invention comprises at least one C-glycoside of formula (I) and the content of the glycoside in the total weight of the composition is 1% to 25% by weight of the active substance, preferably 5% to 18% by weight of the active substance, and more specifically 7% to 15% by weight of the active substance.

[0272] Nicotinamide and its derivatives

[0273] Nicotinamide, also known as nicotinamide, vitamin PP, or vitamin B3, has the following structure (II):

[0274] .

[0275] The term "nicotinamide derivative" preferably refers to a compound in which the amide group in nicotinamide is preferably a secondary amide group or a tertiary amide group substituted with one or two alkyl groups selected individually from C1 to C4 alkyl groups, and / or at least one hydrogen atom on the pyridyl group is substituted with a C1 to C4 alkyl group.

[0276] Preferably, the compound selected from nicotinamide and its derivatives is nicotinamide.

[0277] Niacinamide can be, for example, Niacinamide PC®, commercially available from DSM Nutritional Products.

[0278] The composition comprises a compound selected from nicotinamide and its derivatives, which accounts for 1% to 10% by weight of the total weight of the composition, preferably 0.5% to 8% by weight, and preferably 0.7% to 5% by weight.

[0279] Panthenol

[0280] Panthenol is a precursor of vitamin B5 and has the structure shown in formula (III):

[0281] (III).

[0282] Because panthenol contains an asymmetric carbon atom, it exists as two enantiomers, D and L. Panthenol is preferably D-panthenol (i.e., dextro-panthenol).

[0283] Panthenol can be, for example, commercially available D PANTHEOL CARE® from BASF, DSM Nutrition, or commercially available D PANTHENOL from Hangzhou Xinfu Science & Technology.

[0284] The composition contains panthenol in the total weight of the composition, which accounts for 0.5% to 10% by weight of the active substance, preferably 0.7% to 8% by weight, and preferably 0.8% to 5% by weight.

[0285] Physiologically acceptable media

[0286] The compositions of this invention also include a physiologically acceptable medium. Those skilled in the art can select such a physiologically acceptable medium based on general knowledge related to the type of composition desired.

[0287] As a general principle, the medium can be either anhydrous or aqueous. Therefore, the medium may include an aqueous phase and / or a lipid phase.

[0288] Accordingly, the physiologically acceptable medium preferably includes an aqueous phase and / or a lipid phase.

[0289] The compositions involved in this invention can be formulated into solid, semi-solid, or liquid emulsions.

[0290] Preferably, the composition of the present invention is an aqueous composition.

[0291] "Aqueous composition" means any composition in which water accounts for at least 5% by weight, preferably 5-95% by weight, and more preferably 20-90% by weight in the total weight of the composition.

[0292] Alternatively, the composition of the present invention is preferably an anhydrous composition. "Anhydrous composition" means any composition in which water accounts for less than 5% by weight, more preferably less than 1% by weight, and most preferably less than 0.5% by weight, and preferably any composition that does not contain water.

[0293] The compositions of this invention can be applied topically.

[0294] For application to the skin, this composition may be particularly in the following forms: aqueous or oily solutions; dispersions of the emulsion or serum type; emulsions with liquid or semi-liquid emulsion consistency obtained by dispersing a lipid phase in an aqueous phase (oil / water), an aqueous phase in a lipid phase (water / oil), or a triple dispersion (oil / water / oil or water / oil / water); suspensions or emulsions with cream-like or aqueous or anhydrous gel-like soft consistency; microcapsules or microparticles; ionic and / or nonionic vesicle dispersions.

[0295] When this composition contains an aqueous phase, it contains water, floral water, and / or mineral water.

[0296] The aqueous phase may further contain one or more organic solvents, such as: C1-C8 alcohols, especially ethanol, isopropanol, tert-butanol, n-butanol, pentanol, and hexanol; polyols, such as glycerol, propylene glycol, butanediol, octanediol, isopentanediol, and polyethylene glycol; and polyol ethers.

[0297] When the composition of the present invention is in the form of an emulsion, it may optionally further contain a surfactant, the content of which by weight in the total composition is preferably 0.01 to 30%. The composition of the present invention may further contain at least one co-emulsifier, which may be selected from fatty alcohols such as polyoxyethylene sorbitol monostearate, stearyl alcohol or cetyl alcohol, or fatty acid polyol esters such as glyceryl stearate.

[0298] The compositions of the present invention may further contain a lipid phase, which particularly includes: fats that are liquid at 25°C, such as vegetable, mineral or synthetic oils, optionally volatile oils; fats that are solid at 25°C, such as vegetable, mineral or synthetic waxes; pasty fats; gels; and mixtures thereof.

[0299] Volatile oils generally refer to oils with a saturated vapor pressure of at least 0.5 mbar (i.e. 50 Pa) at 25°C.

[0300] This lipid phase may have the following components:

[0301] - Volatile cyclic polysiloxanes having 3 to 8, preferably 4 to 6, silicon atoms;

[0302] - Polydimethylsiloxane / polymethylalkylsiloxane cyclic polymers;

[0303] - Volatile linear polysiloxanes with 2 to 9 silicon atoms;

[0304] - Volatile hydrocarbon oils, such as isoparaffins, especially isododecane, and fluorinated oils;

[0305] - Polyalkyl (C1~C 20 Siloxanes, especially polyalkyl groups (C1~C4) with trimethylsilyl groups at the end. 20 )siloxanes, such polyalkyl groups (C1~C1) 20 Siloxanes can be linear polydimethylsiloxanes and cetyl polydimethylsiloxanes (CTFA name), etc.

[0306] - Polysiloxanes modified with aliphatic and / or aromatic groups (and optionally fluorinated) or with functional groups such as hydroxyl, mercapto and / or amine groups;

[0307] - Phenylated polysiloxane oil;

[0308] - Vegetable or mineral oils, especially vegetable oils formed from fatty acid polyol esters (especially liquid triglycerides), such as sunflower oil, corn oil, soybean oil, pumpkin seed oil, grape seed oil, sesame oil, hazelnut oil, almond oil, almond oil, or avocado oil; fish oil; caprylic / capric triglycerides; vegetable oils of the formula R1COOR2 (where R1 represents a higher fatty acid residue containing 7 to 19 carbon atoms, and R2 represents a branched hydrocarbon chain containing 3 to 20 carbon atoms), such as PurCellin oil; paraffin oil; petrolatum; perhydrosqualene; wheat germ oil, tamanu oil, sesame oil, macadamia oil, grape seed oil, rapeseed oil, coconut oil, peanut oil, palm oil, castor oil, jojoba oil, olive oil, argan oil, or cereal germ oil; fatty acid esters; alcohols; acetylglycine esters; alcohol or polyol esters of caprylic, capric, or ricinoleic acid; fatty acid triglycerides; glycerides;

[0309] - Fluorinated oils and perfluorinated oils;

[0310] - Polysiloxane adhesive;

[0311] - Waxes of plant, mineral, or synthetic origin, such as microcrystalline wax, paraffin wax, petroleum wax, petrolatum, ceresin wax, lignite wax; beeswax, lanolin wax and its derivatives; candelilla wax, carnauba wax, carnauba wax, Japanese wax, cocoa butter, cork fiber wax or sugarcane wax; hydrogenated oils solid at 25°C, ceresin wax, and fatty acid esters and glycerides solid at 25°C; polyethylene wax, polymethylene wax and waxes obtained by Fehling-Tropsch synthesis; hydrogenated oils solid at 25°C; lanolin wax; fatty acid esters solid at 25°C; polysiloxane wax; fluorinated wax.

[0312] The compositions of the present invention may further contain common adjuvants in the art, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic surfactants (especially surfactants for cosmetic or pharmaceutical applications), preservatives, fragrances, fillers, thickening polymers, chelating agents, pigments, pearlescent agents, ultraviolet filters, deodorizers, and dyes. These adjuvants, depending on their properties, may be incorporated into the lipid phase, aqueous phase, and / or lipid globules.

[0313] Those skilled in the art can, based on common sense, select the properties and amounts of such adjuvants to obtain the desired composition. In any case, those skilled in the art should carefully select any compound to be added and / or its amount so that the advantageous properties of the compositions of the present invention are not, or substantially not, altered by the addition of the compound.

[0314] Preferably, the compositions of the present invention are in particular in the following forms:

[0315] - Facial or body skin care, treatment, cleansing or protection products, such as facial or body (day, night, moisturizing) care compositions; facial anti-wrinkle or anti-aging compositions; facial oil-control compositions; compositions for irritated skin; makeup removal compositions; body lotions, especially for moisturizing (optionally, for after-sun moisturizing);

[0316] - Sunscreen, artificial tanning (self-tanning), or after-sun care products; or

[0317] - Makeup products for the face, body, or lips, such as foundation, tinted moisturizer, blush or eyeshadow, loose powder or pressed powder, concealer stick, concealer stick, lipstick, or lip care products.

[0318] The present invention also relates to a non-therapeutic cosmetic care method for keratin substances, especially skin, comprising: applying the composition of the present invention to keratin substances, especially skin.

[0319] This invention also relates to the cosmetic use of the compositions of this invention in reducing signs of skin aging. Preferably, the signs of skin aging are fine lines, wrinkles, thinning of the epidermis, weakened skin barrier function, and / or sagging and wrinkling of the skin appearance.

[0320] The following describes specific, non-limiting embodiments of the present invention.

[0321] In the following embodiments, unless otherwise stated, temperature refers to ambient temperature (20°C) in degrees Celsius. Furthermore, unless otherwise stated, pressure refers to atmospheric pressure.

[0322] In the following examples, the content of each component of the composition is expressed as a weight percentage (% (w / w)) of the total weight of the composition.

[0323] Example 1: The cosmetic composition of the present invention

[0324] The following compositions of the present invention were prepared according to the following scheme:

[0325] Phase A is heated to 75°C; the various components of phase B1 are mixed and heated to 75°C, and phase B2 is added to prepare phase B; phase B is added to phase A while shearing and stirring at 75°C, and then neutralized with phase C until a homogeneous emulsion is obtained; cooling begins, and phase D is added while shearing and stirring, and phase E is dispersed when the temperature drops below 50°C until a homogeneous emulsion is obtained.

[0326]

[0327] *am = calculated based on active substances

[0328] Example 2: In vitro evaluation of the compound of the present invention

[0329] The in vitro evaluation of the compound of the present invention is as follows.

[0330] In the in vitro evaluation, an aqueous solution containing 10% (w / w) of hydroxypropyl tetrahydropyranotriol, 3% (w / w) of nicotinamide, and 1% (w / w) of D-panthenol (“the compound of the present invention”) was used.

[0331] In addition, an aqueous solution containing only 10% (w / w) of the active substance, hydroxypropyl tetrahydropyranotriol, was used as a reference (“C-glycoside only”).

[0332] Both solutions were tested on recombinant skin models (EpiKutis®) and in vitro models. Both were used to simulate skin aging and to verify the efficacy of the test solutions. The experimental protocol is described below.

[0333] The experiment consisted of two parts. The first part was based on ex vivo skin tissue. The firming effect of the samples was evaluated by detecting changes in the content of elastic fibers, elastin, chondroitin sulfate, and hyaluronic acid, while the anti-wrinkle effect was evaluated by detecting changes in the content of collagen fibers, type III collagen, and type XVII collagen. The second part was based on a three-dimensional epidermal model (EpiKutis®). The soothing effect of the samples was evaluated by detecting changes in the content of inflammatory cytokines (IL-1α, IL-8) and inflammatory mediators (PGE2), while the repair effect was evaluated by detecting changes in the content of filaggrin (FLG).

[0334] Test materials

[0335] Test system:

[0336] The model used in this experiment was a recombinant human epidermal model (EpiKutis®), and the ex vivo skin tissue used in this experiment was provided by Guangdong Biocell Biotechnology Co., Ltd.

[0337] Main reagents:

[0338] In vitro culture medium (Guangdong Boxi Biotechnology), PBS (Solarbio), Vitamin C (Sigma), Vitamin E (Sigma), Type III collagen antibody (Abcam), Type XVII collagen antibody (Abcam), Chondroitin sulfate antibody (Abcam), Paraformaldehyde (Biosharp), Masson reagent kit (Shaanxi Yike Biotechnology), EpiGrowth medium (Guangdong Boxi Biotechnology), IL-1α ELISA kit (Abcam), IL-8 ELISA kit (Abcam), PGE2 ELISA kit (Enzo), FLG antibody (Abcam).

[0339] Main equipment:

[0340] CO2 incubator (Thermo, 150I), clean bench (Suzhou Antai, SW-CJ-1F), microplate reader (BioTek, Epoch), fluorescence microscope (Leica, DM2500), upright microscope (Olympus, BX53), UVA radiometer (Philips), UVB radiometer (Philips).

[0341] Experiments based on ex vivo skin tissue

[0342] Organizational processing:

[0343] Freshly obtained skin tissue was immersed in 75% alcohol for 30 seconds, followed by three washes with sterile PBS buffer. After this, using a disposable sterile skin sampler, the skin tissue was cut into tissue blocks with a fixed surface area of ​​24 ± 2 mm. The processed skin tissue was then placed in a culture chamber with the epidermis facing up and the dermis facing down. The culture chambers were then transferred to 6-well plates, and 3.7 mL of culture medium was added to each well for subsequent incubation at 37°C with 5% CO2. The culture medium was changed daily during the incubation period.

[0344] Application:

[0345] Two days after skin tissue culture, ultraviolet (UV) irradiation and treatment were conducted according to three experimental groups: "untreated skin," "C-glycoside only," and "the compound of this invention," along with corresponding treatment conditions. Skin tissue was exposed to UV irradiation (UVA=30 J / cm², UVB=50 mJ / cm²) for four consecutive days. After each irradiation, fresh culture medium was used, and the sample was subsequently applied to the skin surface. The positive control group (vitamin C + vitamin E) was treated submerged, while the sample groups were treated surface-applied. After four consecutive days of irradiation, the excised skin tissue was cultured for another three days. During this period, no further UV irradiation was performed; only sample application was conducted.

[0346] Collagen fiber testing:

[0347] Skin tissue was fixed in 4% paraformaldehyde, embedded, and sectioned, then stained with Victoria blue and Masson reagent kits, respectively. The results were photographed and analyzed using Image-Pro® Plus software.

[0348] Immunofluorescence assay:

[0349] After the model was circumcised, it was fixed with 4% paraformaldehyde. Immunohistochemical staining and microscopic images were performed 24 hours after fixation.

[0350] Improvement rate calculation:

[0351] Improvement rate (%) = (sample group - negative control group) / (negative control group) × 100%.

[0352] Statistical analysis of results:

[0353] GraphPad Prism was used for plotting analysis, and results were obtained in the form of "mean ± standard deviation". Statistical analysis employed a two-tailed t-test. A p-value < 0.05 was considered statistically significant, and a p-value < 0.01 was considered highly statistically significant.

[0354] Experiment based on EpiKutis®

[0355] Sample working solutions were prepared for the following: "untreated skin", "C-glycosides only", and "the compound of this invention".

[0356] Model application and irradiation:

[0357] 1) Model application: Based on the above experimental groups, the model was transferred into a 6-well plate and randomly divided into a blank control group, a negative control group, a positive control group (containing 0.01% (m / v) dexamethasone), and a sample group, with each group being repeated three times. 0.9 mL of model culture medium was added to each well of the blank control group and the negative control group, and 0.9 mL of model culture medium containing dexamethasone was added to each well of the positive control group. The sample group was applied to the surface.

[0358] 2) UVB irradiation: After application, except for the blank control group, all other groups were irradiated with UVB at a dose of 600mJ / cm².

[0359] 3) Model incubation: After irradiation, the 6-well plate was incubated in a CO2 incubator (37°C, 5% CO2) for 24 hours.

[0360] 4) Cleaning: After incubation, clean the surface of the model with sterile PBS to remove any remaining test material, and wipe away any remaining liquid inside and outside the model with sterile cotton swabs.

[0361] ELISA test:

[0362] After incubation for 24 hours, the culture medium from the three-dimensional epidermal model was collected into centrifuge tubes. After collection, the samples used for ELISA detection were stored in a -80°C freezer and analyzed according to the ELISA kit instructions.

[0363] Immunofluorescence assay:

[0364] The model used for detection was fixed in 4% paraformaldehyde. After 24 hours of fixation, immunofluorescence detection was performed, and microscopic images were taken.

[0365] Calculation of inhibition rate and improvement rate:

[0366] Inhibition rate (%) = (Negative control group - Sample group) / (Negative control group) × 100%,

[0367] Improvement rate (%) = (sample group - negative control group) / (negative control group) × 100%.

[0368] Statistical analysis of results:

[0369] Data analysis was performed using GraphPad Prism software, yielding results in the form of "mean ± standard deviation". Two-tailed t-tests were used for statistical comparisons between groups. A p-value < 0.05 was considered statistically significant, and a p-value < 0.01 was considered highly statistically significant.

[0370] Test results

[0371] The results are summarized in the table below.

[0372] Increase / decrease (%) of the expression of the following markers after UVB irradiation

[0373]

[0374] 1 Increase / decrease in hydroxypropyl tetrahydropyranotriol expression compared to untreated skin (%)

[0375] ²The increase or decrease (%) in expression when using the compound of the present invention (hydroxypropyltetrahydropyranotriol, nicotinamide, and D-panthenol) compared to untreated skin.

[0376] Filamentin is a marker of keratinocyte differentiation and the ability to achieve good barrier function. Filamentin expression decreases when the model experiences skin aging. Filamentin expression increases thanks to the action of C-glycosides, and this effect of the compound of this invention is far greater than that achieved using C-glycosides alone.

[0377] IL-1α, IL-8, and PGE2 are inflammatory markers. These inflammatory markers increase in the epidermis when the model undergoes skin aging. Thanks to the action of C-glycosides, these inflammatory markers are suppressed, and the effect of the compound of this invention is far greater than that achieved using C-glycosides alone.

[0378] Type XVII collagen is a marker of keratinocyte renewal and skin regeneration. When the model experienced skin aging, the expression of type XVII collagen decreased. However, thanks to the action of C-glycosides, type XVII collagen increased, and this effect of the compound of the present invention was far greater than that achieved using C-glycosides alone.

[0379] Collagen fibers are essential for dermal structure. Collagen fiber expression decreased during skin aging in the model. Thanks to the action of C-glycosides, collagen fiber expression increased, and this effect of the compound of this invention was far greater than that achieved using C-glycosides alone.

[0380] Type III collagen is crucial for dermal structure. When the model exhibited skin aging, the expression of type III collagen decreased. However, thanks to the action of C-glycosides, type III collagen expression increased, and this effect of the compound of this invention was far greater than that achieved using C-glycosides alone.

[0381] Chondroitin sulfate, a type of glycosaminoglycan (GAG), is an important component of the extracellular matrix in the dermis. In a skin aging model, the expression of GAG sulfate decreased. However, thanks to the action of C-glycosides, the expression of GAG sulfate increased, and this effect of the compound of this invention was far greater than that achieved using C-glycosides alone.

[0382] Therefore, it is evident that, for the aforementioned eight epidermal and dermal markers, the in vitro efficacy of the compound of this invention is far superior to that of the compound alone. Case using C-glycoside (hydroxypropyl tetrahydropyranotriol) .

Claims

1. A cosmetic composition, characterized in that, Includes components contained in physiologically acceptable media and present in the following proportions by weight of the total composition: At least one C-glycoside of formula (I) comprising 1% to 25% by weight of the active substance; Compounds selected from nicotinamide and its derivatives, comprising 1% to 10% by weight of the active substance; and Panthenol, comprising 0.5% to 10% by weight of the active substance, Equation (I) is as follows: （I） in, - R indicates: - C1~C20, especially C1~C10 saturated straight-chain alkyl, or C2~C20, especially C3~C10 unsaturated straight-chain alkyl, or C3~C20, especially C4~C10 saturated or unsaturated branched or cycloalkyl; - C1~C20, especially C2~C10 saturated straight-chain hydrofluoric or perfluoroalkyl, or C2~C20, especially C2~C10 unsaturated straight-chain hydrofluoric or perfluoroalkyl, or C3~C20, especially C4~C10 saturated or unsaturated branched or cyclic hydrofluoric or perfluoroalkyl; - Phenyl or benzyl, wherein the hydrocarbon chain constituting the group may optionally be interrupted by one, two or more heteroatoms selected from the following heteroatoms, where applicable: - Oxygen atom; - Sulfur atom; - Nitrogen atom; and - Silicon atoms, Furthermore, it may be substituted with at least one of the following groups: - OR4; - -SR4; - -NR4R5; - -COOR4; - -CONHR4; - -CN; - Halogen atom; - C1~C6 hydrofluoric or perfluoroalkyl, and / or - C3~C8 cycloalkyl groups, and / or - At least one optionally substituted C5-C18 cycloalkyl, aryl, or heterocyclic group, R4 and R5 can each represent a hydrogen atom individually, or C1~C30, especially C3~C12 saturated straight-chain alkyl, perfluoroalkyl or hydrofluoroalkyl, or C2~C30, especially C3~C12 unsaturated straight-chain alkyl, perfluoroalkyl or hydrofluoroalkyl, or saturated or unsaturated C3~C30, especially C4~C12 branched or cyclic alkyl, perfluoroalkyl or hydrofluoroalkyl, or C6~C10 aryl; - X represents a group selected from -CO-, -CH(OH)-, and -CH(NH2)-, with -CH(OH)- being preferred; - S represents a monosaccharide in the form of pyranose and / or furanose and in the configuration of L and / or D, or a polysaccharide containing up to 20 sugar units, particularly up to 6 sugar units, wherein the monosaccharide or polysaccharide may be substituted by hydroxyl groups that must remain free, and may be substituted by one or more optional protected amine functional groups; - The S-CH2-X bond represents an anomeric carbon bond, which can be an α-anomeric bond, a β-anomeric bond, or a physiologically acceptable solvate or isomer such as a salt or hydrate.

2. The composition according to claim 1, characterized in that, In the C-glycoside of formula (I): - R represents an unsubstituted C1~C4, especially C1~C2 straight-chain alkyl, especially methyl; - S represents the monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, especially D-xylose; - X represents a group selected from -CO-, -CH(OH)-, and -CH(NH2)-, with -CH(OH)- being preferred.

3. The composition according to claim 1 or 2, characterized in that, The C-glycoside of formula (I) is selected from: 1) C-β-D-xylanopyranoside-n-propan-2-one; 2) C-α-D-xylanopyranoside-n-propyl-2-one; 3) 1-[2-(3-hydroxypropylamino)-propyl]-C-β-D-xylanose; 4) 1-[2-(3-hydroxypropylamino)-propyl]-C-α-D-xylanose; 5) C-β-D-xylanopyranoside-2-hydroxypropane; 6) C-α-D-xylanopyranoside-2-hydroxypropane; 7) C-β-D-xylanopyranoside-2-aminopropane; 8) C-α-D-xylanopyranoside-2-aminopropane; 9) C-β-D-xylanopyranoside-2-phenylaminopropane; 10) C-α-D-xylanopyranoside-2-phenylaminopropane; 11) Ethyl 3-methyl-4-(C-β-D-xylanopyranoside)-butyrate; 12) Ethyl 3-methyl-4-(C-α-D-xylanopyranoside)-butyrate; 13) 6-(C-β-D-xylanopyranoside)-5-oxohexanoic acid; 14) 6-(C-α-D-xylanopyranoside)-5-oxohexanoic acid; 15) 6-(C-β-D-xylanopyranoside)-5-hydroxyhexanoic acid; 16) 6-(C-α-D-xylanopyranoside)-5-hydroxyhexanoic acid; 17) 6-(C-β-D-xylanopyranoside)-5-aminohexanoic acid; 18) 6-(C-α-D-xylanopyranoside)-5-aminohexanoic acid; 19) 6-(C-β-D-xylanopyranoside)-5-phenylaminohexanoic acid; 20) 6-(C-α-D-xylanopyranoside)-5-phenylaminohexanoic acid; 21) 1-(C-β-D-xylanopyranoside)-2,6-hexanediol; 22) 1-(C-α-D-xylanopyranoside)-2,6-hexanediol; 23) 5-(C-β-D-xylanopyranoside)-4-oxovaleric acid; 24) 5-(C-α-D-xylanopyranoside)-4-oxovaleric acid; 25) 5-(C-β-D-xylanopyranoside)-4-hydroxyvalerate; 26) 5-(C-α-D-xylanopyranoside)-4-hydroxyvalerate; 27) 5-(C-β-D-xylanopyranoside)-4-aminovaleric acid; 28) 5-(C-α-D-xylanopyranoside)-4-aminovaleric acid; 29) 5-(C-β-D-xylanopyranoside)-4-phenylaminovaleric acid; 30) 5-(C-α-D-xylanopyranoside)-4-phenylaminovaleric acid; 31) 1-(C-β-D-xylanopyranoside)-2,5-pentanediol; 32) 1-(C-α-D-xylanopyranoside)-2,5-pentanediol; 33) 1-(C-β-D-pyranofucoloside)-propan-2-one; 34) 1-(C-α-D-pyranofucoloside)-propan-2-one; 35) 1-(C-β-L-pyranofucoloside)-propan-2-one; 36) 1-(C-α-L-pyranofucoloside)-propan-2-one; 37) 1-(C-β-D-pyranofucoloside)-2-hydroxypropane; 38) 1-(C-α-D-pyranofucoloside)-2-hydroxypropane; 39) 1-(C-β-L-pyranofucoloside)-2-hydroxypropane; 40) 1-(C-α-L-pyranofucoside)-2-hydroxypropane; 41) 1-(C-β-D-pyranofucoloside)-2-aminopropane; 42) 1-(C-α-D-pyranofucoloside)-2-aminopropane; 43) 1-(C-β-L-pyranofucoloside)-2-aminopropane; 44) 1-(C-α-L-pyranofucoloside)-2-aminopropane; 45) 1-(C-β-D-pyranofucoloside)-2-phenylaminopropane; 46) 1-(C-α-D-pyranofucoloside)-2-phenylaminopropane; 47) 1-(C-β-L-pyranofucoloside)-2-phenylaminopropane; 48) 1-(C-α-L-pyranofucoloside)-2-phenylaminopropane; 49) Ethyl 3-methyl-4-(C-β-D-pyranofucoloside)-butyrate; 50) Ethyl 3-methyl-4-(C-α-D-pyranofucoloside)-butyrate; 51) Ethyl 3-methyl-4-(C-β-L-pyranofucoloside)-butyrate; 52) Ethyl 3-methyl-4-(C-α-L-pyranofucoloside)-butyrate; 53) 6-(C-β-D-pyranofucoloside)-5-oxohexanoic acid; 54) 6-(C-α-D-pyranofucoloside)-5-oxohexanoic acid; 55) 6-(C-β-L-pyranofucoloside)-5-oxohexanoic acid; 56) 6-(C-α-L-pyranofucoloside)-5-oxohexanoic acid; 57) 6-(C-β-D-pyranofucoloside)-5-hydroxyhexanoic acid; 58) 6-(C-α-D-pyranofucoloside)-5-hydroxyhexanoic acid; 59) 6-(C-β-L-pyranofucoloside)-5-hydroxyhexanoic acid; 60) 6-(C-α-L-pyranofucoloside)-5-hydroxyhexanoic acid; 61) 6-(C-β-D-pyranofucoloside)-5-aminohexanoic acid; 62) 6-(C-α-D-pyranofucoloside)-5-aminohexanoic acid; 63) 6-(C-β-L-pyranofucoloside)-5-aminohexanoic acid; 64) 6-(C-α-L-pyranofucoloside)-5-aminohexanoic acid; 65) 1-(C-β-D-pyranofucoloside)-2,6-hexanediol; 66) 1-(C-α-D-pyranofucoloside)-2,6-hexanediol; 67) 1-(C-β-L-pyranofucoloside)-2,6-hexanediol; 68) 1-(C-α-L-pyranofucoloside)-2,6-hexanediol; 69) 5-(C-β-D-pyranofucoloside)-4-oxovaleric acid; 70) 5-(C-α-D-pyranofucoloside)-4-oxovaleric acid; 71) 5-(C-β-L-pyranofucoloside)-2,6-hexanediol)-4-oxovaleric acid; 72) 5-(C-α-L-pyranofucoloside)-2,6-hexanediol)-4-oxovaleric acid; 73) 5-(C-β-D-pyranofucoloside)-4-hydroxyvalerate; 74) 5-(C-α-D-pyranofucoloside)-4-hydroxyvalerate; 75) 5-(C-β-L-pyranofucoloside)-4-hydroxyvalerate; 76) 5-(C-α-L-pyranofucoloside)-4-hydroxyvalerate; 77) 5-(C-β-D-pyranofucoloside)-4-aminovaleric acid; 78) 5-(C-α-D-pyranofucoloside)-4-aminovaleric acid; 79) 5-(C-β-L-pyranofucoloside)-4-aminovaleric acid; 80) 5-(C-α-L-pyranofucoloside)-4-aminovaleric acid; 81) 1-(C-β-D-pyranofucoloside)-2,5-pentanediol; 82) 1-(C-α-D-pyranofucoloside)-2,5-pentanediol; 83) 1-(C-β-L-pyranofucoloside)-2,5-pentanediol; 84) 1-(C-α-L-pyranofucoloside)-2,5-pentanediol; 85) 1-(C-β-D-glucopyranosyl)-2-hydroxypropane; 86) 1-(C-α-D-glucopyranosyl)-2-hydroxypropane; 87) 1-(C-β-D-glucopyranosyl)-2-aminopropane; 88) 1-(C-α-D-glucopyranosyl)-2-aminopropane; 89) 1-(C-β-D-glucopyranosyl)-2-phenylaminopropane; 90) 1-(C-α-D-glucopyranosyl)-2-phenylaminopropane; 91) Ethyl 3-methyl-4-(C-β-D-glucopyranosyl)-butyrate; 92) Ethyl 3-methyl-4-(C-α-D-glucopyranosyl)-butyrate; 93) 6-(C-β-D-glucopyranosyl)-5-oxohexanoic acid; 94) 6-(C-α-D-glucopyranosyl)-5-oxohexanoic acid; 95) 6-(C-β-D-glucopyranosyl)-5-hydroxyhexanoic acid; 96) 6-(C-α-D-glucopyranosyl)-5-hydroxyhexanoic acid; 97) 6-(C-β-D-glucopyranosyl)-5-aminohexanoic acid; 98) 6-(C-α-D-glucopyranosyl)-5-aminohexanoic acid; 99) 6-(C-β-D-glucopyranosyl)-5-phenylaminohexanoic acid; 100) 6-(C-α-D-glucopyranosyl)-5-phenylaminohexanoic acid; 101) 1-(C-β-D-glucopyranosyl)-2,6-hexanediol; 102) 1-(C-α-D-glucopyranosyl)-2,6-hexanediol; 103) 6-(C-β-D-glucopyranosyl)-5-oxovaleric acid; 104) 6-(C-α-D-glucopyranosyl)-5-oxovaleric acid; 105) 6-(C-β-D-glucopyranosyl)-5-hydroxyvalerate; 106) 6-(C-α-D-glucopyranosyl)-5-hydroxyvalerate; 107) 6-(C-β-D-glucopyranosyl)-5-aminovaleric acid; 108) 6-(C-α-D-glucopyranosyl)-5-hydroxyvalerate; 109) 6-(C-β-D-glucopyranosyl)-5-phenylaminovaleric acid; 110) 6-(C-α-D-glucopyranosyl)-5-phenylaminovaleric acid; 111) 1-(C-β-D-glucopyranosyl)-2,5-pentanediol; 112) 1-(C-α-D-glucopyranosyl)-2,5-pentanediol; 113) 1-(C-β-D-galactopyranosyl)-2-hydroxypropane; 114) 1-(C-α-D-galactopyranosyl)-2-hydroxypropane; 115) 1-(C-β-D-galactopyranosyl)-2-aminopropane; 116) 1-(C-α-D-galactopyranosyl)-2-aminopropane; 117) 1-(C-β-D-galactopyranosyl)-2-phenylaminopropane; 118) 1-(C-α-D-galactopyranosyl)-2-phenylaminopropane; 119) Ethyl 3-methyl-4-(β-D-galactopyranosyl)-butyrate; 120) Ethyl 3-methyl-4-(α-D-galactopyranosyl)-butyrate; 121) 6-(C-β-D-galactopyranosyl)-5-oxohexanoic acid; 122) 6-(C-α-D-galactopyranosyl)-5-oxohexanoic acid; 123) 6-(C-β-D-galactopyranosyl)-5-hydroxyhexanoic acid; 124) 6-(C-α-D-galactopyranosyl)-5-hydroxyhexanoic acid; 125) 6-(C-β-D-galactopyranosyl)-5-aminohexanoic acid; 126) 6-(C-α-D-galactopyranosyl)-5-aminohexanoic acid; 127) 6-(C-β-D-galactopyranosyl)5-phenylaminohexanoic acid; 128)6-(C-α-D-galactopyranosyl)5-phenylaminohexanoic acid; 129) 1-(C-β-D-galactopyranosyl)-2,6-hexanediol; 130) 1-(C-α-D-galactopyranosyl)-2,6-hexanediol; 131) 6-(C-β-D-galactopyranosyl)-5-oxovaleric acid; 132) 6-(C-α-D-galactopyranosyl)-5-oxovaleric acid; 133) 6-(C-β-D-galactopyranosyl)-5-hydroxyvalerate; 134) 6-(C-α-D-galactopyranosyl)-5-hydroxyvalerate; 135) 6-(C-β-D-galactopyranosyl)-5-aminovaleric acid; 136) 6-(C-α-D-galactopyranosyl)-5-aminovaleric acid; 137) 6-(C-β-D-galactopyranosyl)-5-phenylaminopentanoic acid; 138) 6-(C-α-D-galactopyranosyl)-5-phenylaminovaleric acid; 139) 1-(C-β-D-galactopyranosyl)-2,6-pentanediol; 140) 1-(C-α-D-galactopyranosyl)-2,6-pentanediol; 141) 1-(C-β-D-furanfucosyl)-propan-2-one; 142) 1-(C-α-D-furanfucosyl)-propan-2-one; 143) 1-(C-β-L-furanfucosyl)-propan-2-one; 144) 1-(C-α-L-furanfucosyl)-propan-2-one; 145) 3'-(acetamido-C-β-D-glucopyranosyl)-prop-2'-one; 146) 3'-(acetamido-C-α-D-glucopyranosyl)-prop-2'-one; 147) 1-(acetamido-C-β-D-glucopyranosyl)-2-hydroxypropane; 148) 1-(acetamido-C-β-D-glucopyranosyl)-2-aminopropane; 149) 1-(acetamido-C-β-D-glucopyranosyl)-2-phenylaminopropane; 150) 1-(acetamido-C-α-D-glucopyranosyl)-2-phenylaminopropane; 151) Ethyl 3-methyl-4-(acetamido-C-β-D-glucopyranoyl)-butyrate 152) Ethyl 3-methyl-4-(acetamido-C-α-D-glucopyranosyl)-butyrate 153) 6-(acetamido-C-β-D-glucopyranosyl)-5-oxohexanoic acid; 154) 6-(acetamido-C-α-D-glucopyranosyl)-5-oxohexanoic acid; 155) 6-(acetamido-C-β-D-glucopyranosyl)-5-hydroxyhexanoic acid; 156) 6-(acetamido-C-α-D-glucopyranosyl)-5-hydroxyhexanoic acid; 157) 6-(acetamido-C-β-D-glucopyranosyl)-5-aminohexanoic acid; 158) 6-(acetamido-C-α-D-glucopyranosyl)-5-aminohexanoic acid; 159) 6-(acetamido-C-β-D-glucopyranosyl)-5-phenylaminohexanoic acid; 160) 6-(acetamido-C-α-D-glucopyranosyl)-5-phenylaminohexanoic acid; 161) 1-(acetamido-C-β-D-glucopyranosyl)-2,6-hexanediol; 162) 1-(acetamido-C-α-D-glucopyranosyl)-2,6-hexanediol; 163) 6-(acetamido-C-β-D-glucopyranosyl)-5-oxovaleric acid; 164) 6-(acetamido-C-α-D-glucopyranosyl)-5-oxovaleric acid; 165) 6-(acetamido-C-β-D-glucopyranosyl)-5-hydroxyvalerate; 166) 6-(acetamido-C-α-D-glucopyranosyl)-5-hydroxyvalerate; 167) 6-(acetamido-C-β-D-glucopyranosyl)-5-aminovaleric acid; 168) 6-(acetamido-C-α-D-glucopyranosyl)-5-aminovaleric acid; 169) 6-(acetamido-C-β-D-glucopyranosyl)-5-phenylaminovaleric acid; 170) 6-(acetamido-C-α-D-glucopyranosyl)-5-phenylaminovaleric acid; 171) 1-(acetamido-C-β-D-glucopyranosyl)-2,5-pentanediol; 172) 1-(acetamido-C-α-D-glucopyranosyl)-2,5-pentanediol, Preferably, the C-glycoside of formula (I) is selected from: - C-β-D-xylanopyranoside-n-propion-2-one; - C-α-D-xylanopyranoside-n-propion-2-one; - C-β-D-xylanopyranoside-2-hydroxypropane; - C-α-D-xylanopyranoside-2-hydroxypropane; - 1-(C-β-D-pyranofucoloside)-propan-2-one; - 1-(C-α-D-pyranofucoloside)-propan-2-one; - 1-(C-β-L-pyranofucoloside)-propan-2-one; - 1-(C-α-L-pyranofucoloside)-propion-2-one; - 1-(C-β-D-pyranofucoloside)-2-hydroxypropane; - 1-(C-α-D-pyranofucoloside)-2-hydroxypropane; - 1-(C-β-L-pyranofucoloside)-2-hydroxypropane; - 1-(C-α-L-pyranofucoloside)-2-hydroxypropane; - 1-(C-β-D-glucopyranosyl)-2-hydroxypropane; - 1-(C-α-D-glucopyranosyl)-2-hydroxypropane; - 1-(C-β-D-galactopyranosyl)-2-hydroxypropane; - 1-(C-α-D-galactopyranosyl)-2-hydroxypropane; - 1-(C-β-D-furanfucosyl)-propan-2-one; - 1-(C-α-D-furanfucosyl)-prop-2-one; - 1-(C-β-L-furanfucosyl)-prop-2-one; - 1-(C-α-L-furanfucosyl)-prop-2-one; - C-β-D-malpyranoside-n-propan-2-one; - C-α-D-pyranomaltoside-n-propan-2-one; - C-β-D-malanopyranoside-2-hydroxypropane; and - C-α-D-pyranomaltoside-2-hydroxypropane.

4. The composition according to any one of the preceding claims, characterized in that, The C-glycoside of formula (I) is selected from C-β-D-xylopyranoside-2-hydroxypropane and C-α-D-xylopyranoside-2-hydroxypropane, preferably C-β-D-xylopyranoside-2-hydroxypropane.

5. The composition according to any one of the preceding claims, characterized in that, The composition includes at least one C-glycoside of formula (I) in a content of 5% to 18% by weight of the active substance, preferably 7% to 15% by weight of the active substance, in the total weight of the composition.

6. The composition according to any one of the preceding claims, characterized in that, The compound selected from nicotinamide and its derivatives is nicotinamide.

7. The composition according to any one of the preceding claims, characterized in that, The composition includes, by weight, 0.5% to 8%, and preferably 0.7% to 5%, of the compounds selected from nicotinamide and its derivatives in the total weight of the composition.

8. The composition according to any one of the preceding claims, characterized in that, The composition includes panthenol, which comprises 0.7% to 8% by weight of the active substance, and preferably 0.8% to 5% by weight, in the total weight of the composition.

9. The composition according to any one of the preceding claims, characterized in that, Includes aqueous phase and / or lipid phase.

10. The composition according to any one of the preceding claims, characterized in that, Forms include: aqueous or oily solutions; dispersions of the emulsion or serum type; emulsions with liquid or semi-liquid emulsion-like consistency obtained by dispersing the lipid phase in an aqueous phase (oil / water), the aqueous phase in a lipid phase (water / oil), or a triple dispersion of oil / water / oil or water / oil / water; suspensions or emulsions with cream-like, aqueous, or anhydrous gel-like soft consistency; microcapsules or microparticles; ionic and / or nonionic vesicle dispersions.

11. The composition according to claim 9, characterized in that, The aqueous phase includes water, floral water, and / or mineral water, and may optionally include one or more organic solvents, such as: C1-C8 alcohols, especially ethanol, isopropanol, tert-butanol, n-butanol, pentanol, and hexanol; polyols, such as glycerol, propylene glycol, butanediol, octanediol, isopentanediol, and polyethylene glycol; and polyol ethers.

12. The composition according to claim 9, characterized in that, The lipid phase includes: fats that are liquid at 25°C, such as vegetable, mineral, or synthetic oils, optionally volatile oils; fats that are solid at 25°C, such as vegetable, mineral, or synthetic waxes; pasty fats; gels; and / or mixtures thereof.

13. A non-therapeutic cosmetic care method targeting keratin substances, especially skin, characterized in that, include: The composition according to any one of claims 1 to 12 is applied to the keratin substance, particularly to the skin.

14. The cosmetic use of the composition according to any one of claims 1 to 12 in reducing signs of skin aging.

15. The cosmetic use as described in claim 14, characterized in that, The signs of skin aging are fine lines, wrinkles, thinning of the epidermis, weakened skin barrier function, and / or sagging and wrinkling of the skin's appearance.

Images